#Denmark #Copenhagen #Adcendo #ADCE-D01 #soft tissue sarcoma

Adcendo Launches ADCElerate1 Trial

Adcendo ApS, a cutting-edge biotechnology firm based in Copenhagen, has recently achieved a significant milestone in cancer treatment with the initiation of its ADCElerate1 clinical trial. This Phase I/II study focuses on the evaluation of ADCE-D01, an innovative antibody-drug conjugate (ADC), specifically designed to target the uPARAP receptor highly expressed in mesenchymal cancers, including various subtypes of soft tissue sarcoma (STS).

The trial represents a vital step in Adcendo's mission to address unmet medical needs in oncology. The first patient has already been dosed at the prestigious Memorial Sloan Kettering Cancer Center in New York, setting the stage for further recruitment across both the United States and Europe. The ADCElerate1 study (NCT06797999) is an open-label, multicenter trial aimed at assessing the safety, tolerability, pharmacokinetics, and preliminary efficacy of ADCE-D01 as a monotherapy for patients suffering from metastatic or unresectable STS. With the recent approval of the European clinical trial application (EUCT number 2024-516900-41-00), the company is poised to broaden its patient recruitment efforts.

Dr. Lone Ottesen, Adcendo's Chief Medical Officer, enthusiastically stated, "The dosing of the first patient in the ADCElerate1 study marks a significant achievement not only for Adcendo but also for the uPARAP program. We are committed to exploring ADCE-D01's potential benefits for patients facing advanced STS." This commitment underscores the urgency of developing effective treatments for those afflicted by mesenchymal cancers, where traditional therapies often fall short.

Professor Robert Maki, a noted sarcoma oncologist at the Department of Musculoskeletal Cancers and Conditions, echoed this sentiment. He remarked on the critical nature of the ADC treatment approach, stating, "We are thrilled to collaborate with Adcendo in advancing ADCE-D01 for advanced STS patients who currently have limited options. ADCs have already played a transformative role in oncology, and we look forward to potentially extending these benefits to our sarcoma patients."

About ADCE-D01

ADCE-D01 is groundbreaking in its formulation, acting as a first-in-class ADC targeting the uPARAP receptor. This receptor plays a crucial role in collagen metabolism and is distinguished by its overexpression in many mesenchymal cancers, including STS and bone sarcoma. Notably, uPARAP shows low expression levels in healthy tissues, which reinforces the therapeutic potential of ADCE-D01 in targeting cancer cells while minimizing damage to normal tissue.

As a pan-mesenchymal cancer targeting ADC, ADCE-D01 stands out as a beacon of hope for patients struggling with these aggressive forms of cancer. Adcendo’s leadership team, comprised of seasoned industry professionals, harnesses their extensive experience in advancing ADC technology to propel innovative cancer treatments to the forefront of medical care.

About Adcendo

Headquartered in Copenhagen, Denmark, with a significant operational presence in Boston, Massachusetts, Adcendo is dedicated to developing pioneering ADC therapies aimed at treating cancers that remain inadequately addressed by current treatments. With a promising pipeline of first-in-class therapies, the company’s approach combines novel target identification, optimized linker-payload strategies, and well-defined clinical development plans. As research progresses and results unfold, Adcendo remains committed to advancing cancer care for the benefit of patients everywhere. For more information, visit Adcendo's official site or connect with them on LinkedIn.